05/01/2026
A timely article from The New York Times today on deprescribing psychiatric medications.
It reflects a conversation that many patients have been having for years, and that clinicians are only starting to more openly engage with. While some psychiatrists mentioned in the article are bringing attention to this, in practice, many patients are still not well supported when it comes to reducing or stopping these medications.
Reading this also made me reflect on my recent experience at the International Conference on Deprescribing.
There were a few sessions and exhibitors discussing this issue, but overall, the focus was much more on polypharmacy in older adults and those with multiple chronic conditions.
And yet, from both patient experiences and established resources like the Maudsley Deprescribing Guidelines and the Benzodiazepine Information Coalition, we know that withdrawal symptoms from psychotropic medications (like antidepressants, anti-anxiety medications, sleeping pills) can be real and, at times, quite significant.
Tapering often needs to be slow, thoughtful, and highly individualized. And when patients are supported through this process, outcomes can be very different.
At the same time, it’s important to recognize that for some individuals, these medications can be helpful and remain an important part of care.
What this highlights for me is the need for more awareness, better education, and stronger support for both patients and clinicians navigating this process.
This is not a fringe issue. It is part of everyday care, and it deserves the same attention as any other area of deprescribing.
With Health Secretary Robert F. Kennedy Jr. aiming to rein in the use of psychiatric drugs, psychiatrists are preemptively addressing how and when patients should quit taking them.